TrialBlood advances2022

Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial.

Lydia Scarfò et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.